Peter Wirth - Net Worth and Insider Trading

Peter Wirth Net Worth

The estimated net worth of Peter Wirth is at least $7 Million dollars as of 2024-05-24. Peter Wirth is the Director of Zai Lab Ltd and owns about 342,763 shares of Zai Lab Ltd (ZLAB) stock worth over $7 Million. Details can be seen in Peter Wirth's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Peter Wirth has not made any transactions after 2022-12-08 and currently still holds the listed stock(s).

Transaction Summary of Peter Wirth

Peter Wirth Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Peter Wirth owns 3 companies in total, including Forma Therapeutics Holdings Inc (FMTX) , Syros Pharmaceuticals Inc (SYRS) , and Zai Lab Ltd (ZLAB) .

Click here to see the complete history of Peter Wirth’s form 4 insider trades.

Insider Ownership Summary of Peter Wirth

Ticker	Comapny	Transaction Date	Type of Owner
FMTX	Forma Therapeutics Holdings Inc	2020-06-18	director
SYRS	Syros Pharmaceuticals Inc	2017-01-27	director
ZLAB	Zai Lab Ltd	2022-12-08	director

Peter Wirth Latest Holdings Summary

Peter Wirth currently owns a total of 1 stock. Peter Wirth owns 342,763 shares of Zai Lab Ltd (ZLAB) as of December 8, 2022, with a value of $7 Million.

Latest Holdings of Peter Wirth

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
ZLAB	Zai Lab Ltd	2022-12-08	342,763	19.06	6,533,063

Holding Weightings of Peter Wirth

Peter Wirth Form 4 Trading Tracker

According to the SEC Form 4 filings, Peter Wirth has made a total of 3 transactions in Zai Lab Ltd (ZLAB) over the past 5 years, including 2 buys and 1 sells. The most-recent trade in Zai Lab Ltd is the sale of 7,852 shares on December 8, 2022, which brought Peter Wirth around $277,568.

Insider Trading History of Peter Wirth

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Peter Wirth Trading Performance

GuruFocus tracks the stock performance after each of Peter Wirth's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Peter Wirth is -48.31%. GuruFocus also compares Peter Wirth's trading performance to market benchmark return within the same time period. The performance of stocks bought by Peter Wirth within 3 months outperforms 0 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Peter Wirth's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Peter Wirth

Average Return

Average return per transaction

Outperforming Transactions

0 out of 2 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	-22.44
Relative Return to S&P 500(%)	-21.93

Peter Wirth Ownership Network

Ownership Network List of Peter Wirth

No Data

Ownership Network Relation of Peter Wirth

Peter Wirth Owned Company Details

What does Forma Therapeutics Holdings Inc do?

Who are the key executives at Forma Therapeutics Holdings Inc?

Peter Wirth is the director of Forma Therapeutics Holdings Inc. Other key executives at Forma Therapeutics Holdings Inc include EVP & Research & Development Agustin Melian , SVP & Chief Scientific Officer David N Cook , and SVP & Chief Financial Officer Todd Shegog .

Forma Therapeutics Holdings Inc (FMTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Forma Therapeutics Holdings Inc (FMTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Forma Therapeutics Holdings Inc (FMTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Forma Therapeutics Holdings Inc (FMTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Forma Therapeutics Holdings Inc Insider Transactions

No Available Data

What does Syros Pharmaceuticals Inc do?

Who are the key executives at Syros Pharmaceuticals Inc?

Peter Wirth is the director of Syros Pharmaceuticals Inc. Other key executives at Syros Pharmaceuticals Inc include Chief Medical Officer David Roth , Chief Scientific Officer Eric R Olson , and Chief Financial Officer Jason Haas .

Syros Pharmaceuticals Inc (SYRS) Insider Trades Summary

Over the past 18 months, Peter Wirth made no insider transaction in Syros Pharmaceuticals Inc (SYRS). Other recent insider transactions involving Syros Pharmaceuticals Inc (SYRS) include a net sale of 30,523 shares made by David Roth , a net purchase of 904,977 shares made by Srinivas Akkaraju , and a net sale of 689 shares made by Eric R Olson .

In summary, during the past 3 months, insiders sold 10,601 shares of Syros Pharmaceuticals Inc (SYRS) in total and bought 0 shares, with a net sale of 10,601 shares. During the past 18 months, 31,212 shares of Syros Pharmaceuticals Inc (SYRS) were sold and 904,977 shares were bought by its insiders, resulting in a net purchase of 873,765 shares.

Syros Pharmaceuticals Inc (SYRS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Syros Pharmaceuticals Inc Insider Transactions

No Available Data

What does Zai Lab Ltd do?

Who are the key executives at Zai Lab Ltd?

Peter Wirth is the director of Zai Lab Ltd. Other key executives at Zai Lab Ltd include Chief Legal Officer Edmondson Frazor Titus Iii , Chief Operating Officer Joshua L Smiley , and See Remarks Rafael Amado .

Zai Lab Ltd (ZLAB) Insider Trades Summary

Over the past 18 months, Peter Wirth made 1 insider transaction in Zai Lab Ltd (ZLAB) with a net sale of 7,852. Other recent insider transactions involving Zai Lab Ltd (ZLAB) include a net sale of 34,897 shares made by Edmondson Frazor Titus Iii , a net purchase of 10,012 shares made by Joshua L Smiley , and a net sale of 23,859 shares made by Rafael Amado .

In summary, during the past 3 months, insiders sold 39,642 shares of Zai Lab Ltd (ZLAB) in total and bought 3,000 shares, with a net sale of 36,642 shares. During the past 18 months, 92,973 shares of Zai Lab Ltd (ZLAB) were sold and 12,000 shares were bought by its insiders, resulting in a net sale of 80,973 shares.

Zai Lab Ltd (ZLAB)'s detailed insider trading history can be found in Insider Trading Tracker table.

Zai Lab Ltd Insider Transactions

No Available Data

Peter Wirth Mailing Address

Above is the net worth, insider trading, and ownership report for Peter Wirth. You might contact Peter Wirth via mailing address: 37 Hancock Street, Boston Ma 02114.

Discussions on Peter Wirth

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.